Switch theme
Sign up to access all valuation multiples
BioInvent International AB is a clinical-stage biotech company. It discovers and develops novel and first-in-class immuno-modulatory antibodies for cancer therapy, with currently four drug candidates in five ongoing clinical programs in Phase 1/2 trials for the treatment of hematological cancer and solid tumors, respectively. The company's validated, proprietary F.I.R.S.T technology platform identifies both targets and the antibodies that bind to them, generating many new drug candidates to fuel the company's clinical development pipeline and providing licensing and partnering opportunities. The company's pipeline portfolio comprises BI-1206, an antagonistic blocking antibody for the treatment of non-Hodgkin’s lymphoma, and BI-1808 and BI-1910 (anti-TNFR2) for solid cancers.
1996
112
LTM Revenue $6.3M
LTM EBITDA -$47.6M
$166M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
BioInvent International has a last 12-month revenue (LTM) of $6.3M and a last 12-month EBITDA of -$47.6M.
In the most recent fiscal year, BioInvent International achieved revenue of $4.6M and an EBITDA of -$43.1M.
BioInvent International expects next 12-month revenue of XXX and NTM EBITDA of XXX
See BioInvent International valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $6.3M | XXX | $4.6M | XXX | XXX | XXX |
| Gross Profit | $6.3M | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | n/a | XXX | XXX | XXX |
| EBITDA | -$47.6M | XXX | -$43.1M | XXX | XXX | XXX |
| EBITDA Margin | -758% | XXX | -934% | XXX | XXX | XXX |
| EBIT | -$51.6M | XXX | -$48.6M | XXX | XXX | XXX |
| EBIT Margin | -823% | XXX | -1055% | XXX | XXX | XXX |
| Net Profit | -$45.7M | XXX | -$44.3M | XXX | XXX | XXX |
| Net Margin | -729% | XXX | -961% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, BioInvent International's stock price is SEK 36 (or $4).
BioInvent International has current market cap of SEK 2.3B (or $241M), and EV of SEK 1.6B (or $166M).
See BioInvent International trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $166M | $241M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, BioInvent International has market cap of $241M and EV of $166M.
BioInvent International's trades at 36.0x EV/Revenue multiple, and -3.9x EV/EBITDA.
Equity research analysts estimate BioInvent International's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
BioInvent International has a P/E ratio of -5.3x.
See valuation multiples for BioInvent International and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $241M | XXX | $241M | XXX | XXX | XXX |
| EV (current) | $166M | XXX | $166M | XXX | XXX | XXX |
| EV/Revenue | 26.5x | XXX | 36.0x | XXX | XXX | XXX |
| EV/EBITDA | -3.5x | XXX | -3.9x | XXX | XXX | XXX |
| EV/EBIT | -3.2x | XXX | -3.4x | XXX | XXX | XXX |
| EV/Gross Profit | 26.5x | XXX | n/a | XXX | XXX | XXX |
| P/E | -5.3x | XXX | -5.4x | XXX | XXX | XXX |
| EV/FCF | -3.4x | XXX | -4.0x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialBioInvent International's last 12 month revenue growth is 231%
BioInvent International's revenue per employee in the last FY averaged $41K, while opex per employee averaged $0.5M for the same period.
BioInvent International's rule of 40 is -207% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
BioInvent International's rule of X is -181% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for BioInvent International and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 231% | XXX | 194% | XXX | XXX | XXX |
| EBITDA Margin | -758% | XXX | -934% | XXX | XXX | XXX |
| EBITDA Growth | -14% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -207% | XXX | -703% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | -181% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $41K | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.5M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 1024% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 1155% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
BioInvent International acquired XXX companies to date.
Last acquisition by BioInvent International was XXXXXXXX, XXXXX XXXXX XXXXXX . BioInvent International acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was BioInvent International founded? | BioInvent International was founded in 1996. |
| Where is BioInvent International headquartered? | BioInvent International is headquartered in Sweden. |
| How many employees does BioInvent International have? | As of today, BioInvent International has 112 employees. |
| Who is the CEO of BioInvent International? | BioInvent International's CEO is Dr. Martin Welschof, PhD. |
| Is BioInvent International publicy listed? | Yes, BioInvent International is a public company listed on STO. |
| What is the stock symbol of BioInvent International? | BioInvent International trades under BINV ticker. |
| When did BioInvent International go public? | BioInvent International went public in 2001. |
| Who are competitors of BioInvent International? | Similar companies to BioInvent International include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of BioInvent International? | BioInvent International's current market cap is $241M |
| What is the current revenue of BioInvent International? | BioInvent International's last 12 months revenue is $6.3M. |
| What is the current revenue growth of BioInvent International? | BioInvent International revenue growth (NTM/LTM) is 231%. |
| What is the current EV/Revenue multiple of BioInvent International? | Current revenue multiple of BioInvent International is 26.5x. |
| Is BioInvent International profitable? | Yes, BioInvent International is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of BioInvent International? | BioInvent International's last 12 months EBITDA is -$47.6M. |
| What is BioInvent International's EBITDA margin? | BioInvent International's last 12 months EBITDA margin is -758%. |
| What is the current EV/EBITDA multiple of BioInvent International? | Current EBITDA multiple of BioInvent International is -3.5x. |
| What is the current FCF of BioInvent International? | BioInvent International's last 12 months FCF is -$49.4M. |
| What is BioInvent International's FCF margin? | BioInvent International's last 12 months FCF margin is -788%. |
| What is the current EV/FCF multiple of BioInvent International? | Current FCF multiple of BioInvent International is -3.4x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
